Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
8.44
+0.86 (11.32%)
Mar 9, 2026, 3:39 PM EDT - Market open
Decoy Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
4.49M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GeoVax Labs | 3.35M |
| HCW Biologics | 422.03K |
| BioRestorative Therapies | 383.40K |
| Bio Green Med Solution | 81.00K |
| Silo Pharma | 72.10K |
DCOY News
- 4 days ago - Decoy Therapeutics Announces 1-for-12 Reverse Stock Split - PRNewsWire
- 26 days ago - Decoy Therapeutics Joins Webull Corporate Connect Service Platform - PRNewsWire
- 4 weeks ago - Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - PRNewsWire
- 4 weeks ago - Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - PRNewsWire
- 7 weeks ago - Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PRNewsWire
- 2 months ago - Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform - GlobeNewsWire